• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Restructuring and layoffs please use this new thread for updates

Quote
After being lied to and shit on since being dumped here from CV I really don't give af what you do with me! Shame on you all at Janssen! You hide behind a pretend credo! Fuck you all!
 




!!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!! !!!!!!!The PONVORY nightmare is over!!!!!
 




















anonymous said:
Reductions have been made in various parts of the org: RND, support functions and commercial. IDV, CVMRPH and Neuro commercial and RND have had the most changes from what I have seen. If your entire commercial/sales org has been gutted, the org sees limited near term sales contributions, from the internal pipeline or external possibilities. RND in those divisions better deliver and very quickly.
Oncology and Immunology have the best potential for delivering, both on the short and long term. Again, even they need to continue to actually deliver.
Since changes are occuring across the global organization, it will take some time to get a clear picture.
Every pharma company is facing a unique range of challenges, and how that plays out over the future will influence what additional changes are made at each company. Our areas include consumer spin out, exposure to litigation, actual booked sales and impact of LOE, the IRA in the US and reimbursement pressure in Europe, inflationary pressure.
Click to expand...

Did anything happen to data sciences?
 








anonymous said:
Reductions have been made in various parts of the org: RND, support functions and commercial. IDV, CVMRPH and Neuro commercial and RND have had the most changes from what I have seen. If your entire commercial/sales org has been gutted, the org sees limited near term sales contributions, from the internal pipeline or external possibilities. RND in those divisions better deliver and very quickly.
Oncology and Immunology have the best potential for delivering, both on the short and long term. Again, even they need to continue to actually deliver.
Since changes are occuring across the global organization, it will take some time to get a clear picture.
Every pharma company is facing a unique range of challenges, and how that plays out over the future will influence what additional changes are made at each company. Our areas include consumer spin out, exposure to litigation, actual booked sales and impact of LOE, the IRA in the US and reimbursement pressure in Europe, inflationary pressure.
Click to expand...
Thank you so much. If you ever get laid off, you have a great future in the comms department.
 




anonymous said:
To whomever wrote the information above - thank you for being more transparent in one anonymous blog than in the countless townhall we have attended to date.
Click to expand...

You are welcome. I used to work at BMS. They were much clearer in how they communicated layoffs. These times suck, but we all deserve clear communication.
Truth be told, my boss's boss is the best and keeps us well informed.
 








Katie Devine explicitly announced during a town hall that there will not be ANY further changes to CVM. Whoever said CVM will see cuts is wrong.

vaccines is no longer going to be part of the U.S. commercial company. It’s getting moved to global. Consequently all the supporting NA Pharm roles for vaccines are also being eliminated.
 




anonymous said:
Katie Devine explicitly announced during a town hall that there will not be ANY further changes to CVM. Whoever said CVM will see cuts is wrong.

vaccines is no longer going to be part of the U.S. commercial company. It’s getting moved to global. Consequently all the supporting NA Pharm roles for vaccines are also being eliminated.
Click to expand...

Isn't there going to be a new head of R&D soon? With new managements usually comes new additional changes?
 




anonymous said:
Isn't there going to be a new head of R&D soon? With new managements usually comes new additional changes?
Click to expand...

There will definitely be changes implemented by the new head of R&D. If the new head is an internal promotion, we may see those changes sooner than if they hire someone from the outside. Hopefully those changes will only result in organization without a headcount reduction, but who knows.
 




anonymous said:
There will definitely be changes implemented by the new head of R&D. If the new head is an internal promotion, we may see those changes sooner than if they hire someone from the outside. Hopefully those changes will only result in organization without a headcount reduction, but who knows.
Click to expand...
Is the Mathai dude out yet, or what?
 
















anonymous said:
There will definitely be changes implemented by the new head of R&D. If the new head is an internal promotion, we may see those changes sooner than if they hire someone from the outside. Hopefully those changes will only result in organization without a headcount reduction, but who knows.
Click to expand...
I heard they may have finalized who will it be. But they are waiting for the dust to be settled from layoffs before announcing the new lead.
 








Top Bottom
Back
Quote